Shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $31.75.

BHVN has been the subject of several research analyst reports. Barclays PLC initiated coverage on Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued an “overweight” rating and a $30.00 price objective for the company. Piper Jaffray Companies initiated coverage on Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued an “overweight” rating and a $21.00 price objective for the company. Needham & Company LLC initiated coverage on Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued a “buy” rating and a $30.00 price objective for the company. William Blair initiated coverage on Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued an “outperform” rating and a $46.00 price objective for the company. Finally, Morgan Stanley initiated coverage on Biohaven Pharmaceutical Holding Co in a research note on Wednesday, May 31st. They issued an “overweight” rating for the company.

ILLEGAL ACTIVITY WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Given Consensus Recommendation of “Buy” by Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/10/biohaven-pharmaceutical-holding-co-ltd-bhvn-given-consensus-recommendation-of-buy-by-brokerages.html.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 38.12 on Friday. The stock’s market capitalization is $1.37 billion. Biohaven Pharmaceutical Holding Co has a 12 month low of $17.00 and a 12 month high of $38.56. The company’s 50 day moving average price is $29.28 and its 200 day moving average price is $25.82.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.